Innovative gel offers hope against resistant infections in trial

Recce Pharmaceuticals has announced promising outcomes from the Phase II trial of their innovative RECCE 327 Topical Gel (R327G), signaling a potential breakthrough in the fight against antibiotic-resistant infections. 

This new gel is being developed to treat Acute Bacterial Skin and Skin Structure Infections (ABSSSI), offering hope where traditional treatments falter.

The trial recently completed dosing 30 participants and the preliminary results are in: R327G appears not only effective but also safe, with no Serious Adverse Events reported among the participants. These findings suggest that R327G could be a game-changer for those suffering from severe bacterial infections.

Recce plans to initiate a Phase III trial in Australia in early 2025. This study aims to secure approvals from major regulatory bodies like the FDA and the Australian Therapeutic Goods Administration (TGA). Additionally, the company is preparing to launch one of the largest trials for diabetic foot infections in Indonesia, positioning R327G to make a significant impact in the ASEAN region.

With the global ABSSSI treatment market poised for growth, Recce’s developments could not be more timely. The company continues to advance its portfolio of synthetic anti-infectives, each designed to take on the formidable challenge of antimicrobial resistance head-on.

Picture: credit Recce